Madhavbaug, the flagship brand of NSE listed Vaidya Sane Ayurved Laboratories Ltd, has reported reported a 122.27 per cent growth in profit after tax (PAT) for the half year ended September 2022. Madhavbaug’s PAT jumped to Rs 3.01 crore during the April – September period this fiscal from Rs 1.35 crore recorded during the corresponding period last year.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

Madhavbaug saw its gross revenue increase to Rs 45.52 crore during the first half of FY23, up 45.15 per cent from Rs 31.36 crore reported during the year ago period.

"The robust all-round performance came on the back of several new initiatives taken by Madhavbaug that had led to significant increase in the number of patients seeking ayurvedic remedies. Besides enormous response to Ayurvedic diet products like ‘Madhav Shakti Atta’ during the last six months, Madhavbaug also further strengthened its Tele Medicine facility to make Ayurvedic treatment accessible to even people living in the remotest part of the country," an official statement said.

“People's trust and confidence in India’s ancient healthcare science has grown manifold over the last few years. We continued our focus on efficient patient service through several new initiatives including the use of technology and collaboration with leading industry players to increase the reach and scope of our service offerings. I am delighted to share that Madhavbaug managed to serve 12,768 patients across its healthcare clinics during the first half of the current fiscal. This is when compared to 17,382 patients we served during the whole of FY22. This shows that several measures taken by Madhavbuag to increase the awareness and treatment facilities coupled with strong support received by industry from the government led by Honourable Prime Minister Narendra Modi have created a very positive impact at the ground level,” said Dr Rohit Sane, MD & CEO, Vaidya Sane Ayurved Laboratories Ltd (Madhavbaug).